Table 4 Safety outcomes
Group L (n = 25) | Group R (n = 25) | P-value | |
|---|---|---|---|
Epistaxis during intubation | > 0.999 | ||
None | 18 (72%) | 17 (68%) | |
Mild | 6 (24%) | 6 (24%) | |
Medium | 1 (4%) | 2 (8%) | |
Severe | 0 (0%) | 0 (0%) | |
Adverse events during intubation | |||
Total incidence | 6 (24%) | 4 (16%) | 0.480 |
Hypotensiona | 5 (20%) | 4 (16%) | > 0.999 |
Bradycardiab | 1 (4%) | 0 (0%) | > 0.999 |
Postoperative 24 h adverse events | |||
Total incidence | 9 (36%) | 9 (36%) | > 0.999 |
Continuous epistaxis | 3 (12%) | 2 (8%) | > 0.999 |
Pain of the nose | 1 (4%) | 1 (4%) | > 0.999 |
Nasal obstruction | 2 (8%) | 1 (4%) | > 0.999 |
Sore throat | 8 (32%) | 6 (24%) | 0.529 |
Severe damage of airway | 0 (0%) | 0 (0%) | – |